Tag: Migraine
Fremanezumab Linked to Fewer Monthly Migraine Days
For episodic migraine patients, reduction in number of migraine days with monthly dosing, single dose
AAN: Erenumab Shows Promise for Hard-to-Treat Migraine
Higher proportion of patients achieved a ≥50 percent reduction in mean monthly migraine days
Noninvasive Brain Stimulation May Help Prevent Migraines
Single-pulse transcranial magnetic stimulation device is safe and easy to use
Low Risk of Serotonin Syndrome for Triptans + SSRI/SNRI
Researchers question FDA advisory warning on risk of concomitant use
Migraine Linked to Increased Risk of Cardiovascular Disease
Increased risks of myocardial infarction, ischemic and hemorrhagic stroke, VTE, A-fib, and flutter
Pain Self-Efficacy Questionnaire Helps to Evaluate Migraine Pain
Commonly used pain survey better assesses migraine patients' pain-coping ability and function
Fremanezumab, Erenumab Effective in Treatment of Migraine
Fremanezumab effective in chronic migraine; erenumab beneficial for episodic migraine
ASA: Botox Injections Beneficial for Migraine in Children
Statistically significant changes in migraine intensity, frequency, duration from pre- to post-therapy
ASA: Ketamine Infusions May Relieve Pain in Migraine
Least pain on day 4, achieved at mean ketamine rates of 30.8±3.6 mg/hr less than maximum dose
IV Prochlorperazine Beats IV Hydromorphone for Migraine
IV hydromorphone much less effective for migraine treatment in the emergency department
